Advances in Mechanism Research of Diabetes and Insulin Resistance

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Endocrinology and Metabolism Research".

Deadline for manuscript submissions: 30 May 2024 | Viewed by 1857

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates
Interests: diabetes mellitus; insulin resistance; AGEs; inflammation; oxidative stress; epigenetic modifications; insulin signal perturbations

E-Mail Website
Guest Editor
Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, São Paulo 01506-000, Brazil
Interests: insulin resistance; type 2 diabetes mellitus; obesity; mitochondrial function; metabolism; insulin signaling

Special Issue Information

Dear Colleagues,

Diabetes is a chronic disease that affects millions of people worldwide, making it one of the biggest challenges of the 21st century. Hyperglycemia, leading to the generation of advanced glycations end products, and insulin resistance, leading to metabolic disorders and pancreatic beta cell death, are the major contributors to the development of type 2 diabetes mellitus. Insulin resistance is a complex condition where the body's cells become less sensitive to insulin, impairing its downstream metabolic actions, including the normalization of the serum glucose concentrations. Over the past few decades, mechanisms underlying diabetes and insulin resistance have been the subject of intense research, which has resulted in several key advancements. An increasing body of work has linked hyperglycemic memory, metabolic inflammation, lipid accumulation, advanced glycation end products (AGEs), mitochondrial dysfunction, oxidative stress, microbiota composition, and epigenetics changes with insulin resistance and diabetes mellitus. This Special Issue, entitled “Advances in Mechanism Research of Diabetes and Insulin Resistance”, will focus on all of these mechanistic aspects. This Special Issue aims to link advances in the mechanisms underlying diabetes and insulin resistance to the development of new treatments and management strategies. Targeting inflammation, improving mitochondrial function, reducing lipid accumulation, modulating the gut microbiota, and addressing epigenetic and hormonal factors are all potential avenues for future research and treatment development.

We are delighted to invite authors to submit original research and review articles related to multiple aspects of insulin resistance and diabetes mellitus. In this regard, special attention will be paid to novel mechanistic perspectives to develop more effective prevention and treatment strategies.

We look forward to receiving your contributions.

Prof. Dr. Abdu Adem
Dr. Sandro Massao Hirabara
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 380 KiB  
Review
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
by Muna A. Adem, Boris Decourt and Marwan N. Sabbagh
Biomedicines 2024, 12(1), 99; https://doi.org/10.3390/biomedicines12010099 - 03 Jan 2024
Viewed by 1504
Abstract
Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are chronic, progressive disorders affecting the elderly, which fosters global healthcare concern with the growing aging population. Both T2DM and AD have been linked with increasing age, advanced glycosylation end products, obesity, and insulin [...] Read more.
Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are chronic, progressive disorders affecting the elderly, which fosters global healthcare concern with the growing aging population. Both T2DM and AD have been linked with increasing age, advanced glycosylation end products, obesity, and insulin resistance. Insulin resistance in the periphery is significant in the development of T2DM and it has been posited that insulin resistance in the brain plays a key role in AD pathogenesis, earning AD the name “type 3 diabetes”. These clinical and epidemiological links between AD and T2DM have become increasingly pronounced throughout the years, and serve as a means to investigate the effects of antidiabetic therapies in AD, such as metformin, intranasal insulin, incretins, DPP4 inhibitors, PPAR-γ agonists, SGLT2 inhibitors. The majority of these drugs have shown benefit in preclinical trials, and have shown some promising results in clinical trials, with the improvement of cognitive faculties in participants with mild cognitive impairment and AD. In this review, we have summarize the benefits, risks, and conflicting data that currently exist for diabetic drugs being repurposed for the treatment of AD. Full article
(This article belongs to the Special Issue Advances in Mechanism Research of Diabetes and Insulin Resistance)
Show Figures

Graphical abstract

Back to TopTop